SURPASS–CVOT
The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes
- Stadium
- klaar
- Middel
- Tirzepatide
- Populatie
- Diabetes Mellitus
- Fase
- III
- First Patient In
- 23 september 2020
- Last Patient In
- 31 augustus 2021
- Last Patient Last Visit
- 1 mei 2025
National Lead
dr. A.F.M. Kuijper
Cardioloog
Studiedirecteur
dr. F.J.F. Broeyer
Cardioloog
Contact Kantoor
